Suppr超能文献

磺酰脲类抗糖尿病药与院外心脏骤停风险降低相关:基于人群的真实世界研究数据。

Sulfonylurea antidiabetics are associated with lower risk of out-of-hospital cardiac arrest: Real-world data from a population-based study.

机构信息

Department of Cardiology, Heart Center, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.

出版信息

Br J Clin Pharmacol. 2021 Sep;87(9):3588-3598. doi: 10.1111/bcp.14774. Epub 2021 Apr 25.

Abstract

AIMS

Out-of-hospital cardiac arrest (OHCA) mostly results from ventricular tachycardia/ventricular fibrillation (VT/VF), often triggered by acute myocardial infarction (AMI). Sulfonylurea (SU) antidiabetics can block myocardial ATP-regulated K channels (K channels), activated during AMI, thereby modulating action potential duration (APD). We studied whether SU drugs impact on OHCA risk, and whether these effects are related to APD changes.

METHODS

We conducted a population-based case-control study in 219 VT/VF-documented OHCA cases with diabetes and 697 non-OHCA controls with diabetes. We studied the association of SU drugs (alone or in combination with metformin) with OHCA risk compared to metformin monotherapy, and of individual SU drugs compared to glimepiride, using multivariable logistic regression analysis. We studied the effects of these drugs on APD during simulated ischaemia using patch-clamp studies in human induced pluripotent stem cell-derived cardiomyocytes.

RESULTS

Compared to metformin, use of SU drugs alone or in combination with metformin was associated with reduced OHCA risk (OR 0.6 [95% CI 0.4-0.9], OR 0.6 [95% CI 0.4-0.9]). We found no differences in OHCA risk between SU drug users who suffered OHCA inside or outside the context of AMI. Reduction of OHCA risk compared to glimepiride was found with gliclazide (OR 0.5 [95% CI 0.3-0.9]), but not glibenclamide (OR 1.3 [95% CI 0.6-2.7]); for tolbutamide, the association with reduced OHCA risk just failed to reach statistical significance (OR 0.6 [95% CI 0.3-1.002]). Glibenclamide attenuated simulated ischaemia-induced APD shortening, while the other SU drugs had no effect.

CONCLUSIONS

SU drugs were associated with reduced OHCA risk compared to metformin monotherapy, with gliclazide having a lower risk than glimepiride. The differential effects of SU drugs are not explained by differential effects on APD.

摘要

目的

院外心脏骤停(OHCA)主要由室性心动过速/室颤(VT/VF)引起,常由急性心肌梗死(AMI)触发。磺酰脲类(SU)抗糖尿病药物可阻断心肌 ATP 调节的钾通道(K 通道),在 AMI 期间被激活,从而调节动作电位持续时间(APD)。我们研究了 SU 药物是否会影响 OHCA 风险,以及这些作用是否与 APD 变化有关。

方法

我们在 219 例 VT/VF 记录的 OHCA 糖尿病病例和 697 例非 OHCA 糖尿病对照中进行了一项基于人群的病例对照研究。我们研究了与二甲双胍相比,SU 药物(单独或与二甲双胍联合使用)与 OHCA 风险的关系,以及与格列美脲相比,单独使用 SU 药物与 OHCA 风险的关系,使用多变量逻辑回归分析。我们使用人诱导多能干细胞衍生的心肌细胞中的膜片钳研究来研究这些药物在模拟缺血期间对 APD 的影响。

结果

与二甲双胍相比,SU 药物单独或联合使用与 OHCA 风险降低相关(OR 0.6 [95%CI 0.4-0.9],OR 0.6 [95%CI 0.4-0.9])。我们没有发现 SU 药物使用者在 AMI 内外发生 OHCA 的风险差异。与格列美脲相比,格列齐特降低 OHCA 风险(OR 0.5 [95%CI 0.3-0.9]),但格列本脲(OR 1.3 [95%CI 0.6-2.7])没有;对于甲苯磺丁脲,与降低 OHCA 风险的关联仅未达到统计学意义(OR 0.6 [95%CI 0.3-1.002])。格列本脲减弱了模拟缺血引起的 APD 缩短,而其他 SU 药物则没有影响。

结论

与二甲双胍单药治疗相比,SU 药物与 OHCA 风险降低相关,格列齐特的风险低于格列美脲。SU 药物的不同作用不能用对 APD 的不同作用来解释。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e84c/8453495/3ab5b33418c8/BCP-87-3588-g002.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验